logo-loader
viewMedexus Pharmaceuticals Inc

Medexus Pharmaceuticals sees steady growth across key product lines as it updates on IXINITY acquisition

The firm closed its acquisition of Aptevo BioTherapeutics LLC, which owns the worldwide rights to IXINITY from Nasdaq-listed Aptevo Therapeutics on February 28

Medexus Pharmaceuticals Inc -
Medexus said the revenue from IXINITY for March is in line with its expectations

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) told investors that the acquisition of hematology asset IXINITY had been highly accretive to the firm in its fiscal fourth quarter and that it was well positioned to emerge stronger when the economy reopens after the coronavirus (COVID-19) crisis.

The firm closed its acquisition of Aptevo BioTherapeutics LLC, which owns the worldwide rights to IXINITY from Nasdaq-listed Aptevo Therapeutics Inc, on February 28 this year and integration of the product is progressing as expected.

READ: Medexus Pharmaceuticals secures US$20M credit facility, pays off term loan

Medexus sees significant further growth potential for sales as it leverages its expanded sales force in the US. To that end, Michael Adelman, from Aptevo, has been appointed general manager of Medexus’ US operations.

Medexus said its fiscal fouth quarter ended March 31, 2020, included two months of pre-acquisition sales and one month post-acquisition.

Preliminary unaudited sales estimates for IXINITY during the fiscal fourth quarter was US$8.3 million, representing an 18.5% year-over-year increase, noted Medexus.

"Approximately 85% of those IXINITY sales accrued to the benefit of Medexus post-acquisition and as such, the addition of IXINITY was highly accretive to Medexus for the quarter," it added.

The revenues from IXINITY for March 2020 are in line with Medexus' expectations, it added.

On May 7, Medexus announced the completion of a financing deal with MidCap Financial Trust on a secured 38 month revolving credit facility.

The ABL Facility features a US$20 million revolving commitment and uncommitted US$10 million accordion. The financing package allowed Medexus to finance the acquisition without issuing further shares, it said.

On the pandemic, Medexus said it continues to address operational challenges posed by the virus but it has largely been successful in conducting business as usual.

So far, no employees have reported testing positive for the COVID-19 virus, said the company.

"Medexus’ business remains strong and is well positioned to emerge even stronger as the economy reopens," Medexus chairman Peter van der Velden said in a statement.

"We continue to generate steady growth across our key product lines and, despite the disruption from the COVID-19 pandemic, our sales teams have continued to be remarkably productive by finding new ways to connect creatively and productively with clinicians and patients.

"As much of our portfolio is used to treat chronic conditions, we continue to see strong demand for our products, including our new hematology product, IXINITY. While continuing to be very disciplined about how we manage our cash, we are excited about the expanding list of compelling business development opportunities our team is evaluating."

Shares in Toronto added over 12% at C$2.81 each.

---Updates for share price---

Contact the author at [email protected]

Quick facts: Medexus Pharmaceuticals Inc

Price: 2.5 CAD

TSX-V:MDP
Market: TSX-V
Market Cap: $35.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medexus Pharmaceuticals pleased with recent Aptevo BioTherapeutics...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive he's pleased with the value the acquisition of hematology asset IXINITY has provided to Medexus, and that it is well positioned to emerge stronger when the economy reopens after the coronavirus crisis....

1 week ago

3 min read